FHTX Foghorn Therapeutics Inc.
Healthcare$4.37+3.55%ClosedMarket Cap: $256.6M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
-3.84
P/S
8.78
EV/EBITDA
-2.78
DCF Value
$-12.90
FCF Yield
-35.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
22.3%
Operating Margin
-286.2%
Net Margin
-266.9%
ROE
85.8%
ROA
-33.9%
ROIC
-50.6%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $3.3M | 92.7% | $-21.6M | $-19.9M | $— | — |
| Q4 null | $9.2M | 91.3% | $-19.6M | $-21.7M | $— | — |
| FY null | $30.9M | 89.2% | $-82.1M | $-74.3M | $— | — |
| Q3 null | $8.2M | -145.3% | $-18.5M | $-15.8M | $— | — |
| Q2 null | $7.6M | 88.1% | $-21.1M | $-17.9M | $— | — |
| Q1 null | $6.0M | 100.0% | $-22.9M | $-18.8M | $— | — |
| Q4 null | $2.9M | 100.0% | $-24.0M | $-19.5M | $— | — |
| FY null | $22.6M | 100.0% | $-102.7M | $-86.6M | $— | — |
| Q3 null | $7.8M | 100.0% | $-23.9M | $-19.1M | $— | — |
| Q2 null | $6.9M | 100.0% | $-26.6M | $-23.0M | $— | — |
| Q1 null | $5.0M | 100.0% | $-28.2M | $-25.0M | $— | — |
| Q4 2023 | $5.8M | 85.2% | $-25.5M | $-24.1M | $-0.57 | — |